Sanofi, Regeneron unveil 'blow-out' smoker's lung drug data
Drug meets primary and all secondary goals in COPD trial
Previous peak sales estimate of 13 bln euros was without COPD
Drug could be first new COPD treatment in over a decade
Adds Regeneron price, paragraph 5
By Ludwig Burger
March 23 (Reuters) -Sanofi's SASY.PA asthma drug Dupixent met all targets in a trial to treat "smoker's lung", potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.
In a late stage trial Dupixent, jointly developed with Regeneron REGN.O, led to a 30% reduction in moderate or severe acute exacerbations of chronic obstructive pulmonary disease (COPD), a potentially deadly disease marked by progressive lung function decline.
Shares in Sanofiand Regeneron surged after they saidin a joint statementon Thursday a Phase III trial involving 939 current or former smokers also showed improvements in lung function, quality of life and respiratory symptoms.
The French group's stock was up 5.2% at 1205 GMT, reaching a seven-month high and far outperforming the STOXX Europe 600 Health Care index .SXDP, which was little changed.
Regeneron jumped 8.6% in U.S. premarket trade and was set to open at a record high.
"COPD is an urgent global health concern and a notoriously difficult-to-treat disease due to its heterogeneity, with no novel treatments approved in more than a decade," said Regeneron Chief Scientific Officer George Yancopoulos.
Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time.
JP Morgan analyst Richard Vosser said the trial update had "blow-out data" in store for investors, and that market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros.
"We see Dupixent data in COPD exceeding any expectations in the market for benefit," the analyst said.
Jefferies analysts said the update yielded "perhaps best case efficacy" to treat the disease.
Sanofi previously forecast Dupixent would generate up to 13 billion euros ($14.2 billion) in sales in its best year as it seeks to widen its use across several inflammatory conditions, but it has excluded COPD from its sales target.
Sanofi said on Thursday it was too early to update its sales estimate for the product, which is also used to ease eczema.
The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19% of the French group's overall sales of 43 billion euros, last year. That was a currency-adjusted increase of 44% from a year earlier.
Sanofi reports combined global Dupixent sales from its alliance with Regeneron.
The companies said that full efficacy and safety results would be presented later. They added a second late-stage COPD Dupixent trial was ongoing, with the first data read-out expected next year.
Overall rates of adverse events in the trial reporting results were 77% for Dupixent and 76% for placebo.
Sanofi shares have been battered following disappointing trial results in August 2022 of a once-promising breast cancer drug candidate.
Legal claims that heartburn drug Zantac caused cancer have also weighed on the stock.
The group, led by British CEO Paul Hudson, this month struck a deal to acquire Provention Bio Inc PRVB.O for $2.9 billion to bolster its work on a U.S.-approved type 1 diabetes therapy.
Analysts have said that this year's expected market debut of two new products, to balance out reliance on Dupixent, would be important tests of the company's marketing and development prowess and a chance to regain investor confidence.
These products are haemophilia A treatment Altuviiio, requiring fewer injections than standard therapy, and Beyfortus from a partnership with AstraZeneca AZN.L, which is a preventive injection against the common RSV airways infection in infants.
Sanofi and Regeneron on Tuesday announced the European Commission had approved Dupixent to treat severe atopic dermatitis in young children. Prior to that, the drug was also approved in Europe to treat a type of esophagus inflammation.
($1 = 0.9168 euros)
Reporting by Ludwig Burger in Frankfurt and Juby Babu in Bengaluru; editing by Mark Potter and Jason Neely
면책조항: XM Group 회사는 체결 전용 서비스와 온라인 거래 플랫폼에 대한 접근을 제공하여, 개인이 웹사이트에서 또는 웹사이트를 통해 이용 가능한 콘텐츠를 보거나 사용할 수 있도록 허용합니다. 이에 대해 변경하거나 확장할 의도는 없습니다. 이러한 접근 및 사용에는 다음 사항이 항상 적용됩니다: (i) 이용 약관, (ii) 위험 경고, (iii) 완전 면책조항. 따라서, 이러한 콘텐츠는 일반적인 정보에 불과합니다. 특히, 온라인 거래 플랫폼의 콘텐츠는 금융 시장에서의 거래에 대한 권유나 제안이 아닙니다. 금융 시장에서의 거래는 자본에 상당한 위험을 수반합니다.
온라인 거래 플랫폼에 공개된 모든 자료는 교육/정보 목적으로만 제공되며, 금융, 투자세 또는 거래 조언 및 권고, 거래 가격 기록, 금융 상품 또는 원치 않는 금융 프로모션의 거래 제안 또는 권유를 포함하지 않으며, 포함해서도 안됩니다.
이 웹사이트에 포함된 모든 의견, 뉴스, 리서치, 분석, 가격, 기타 정보 또는 제3자 사이트에 대한 링크와 같이 XM이 준비하는 콘텐츠 뿐만 아니라, 제3자 콘텐츠는 일반 시장 논평으로서 "현재" 기준으로 제공되며, 투자 조언으로 여겨지지 않습니다. 모든 콘텐츠가 투자 리서치로 해석되는 경우, 투자 리서치의 독립성을 촉진하기 위해 고안된 법적 요건에 따라 콘텐츠가 의도되지 않았으며, 준비되지 않았다는 점을 인지하고 동의해야 합니다. 따라서, 관련 법률 및 규정에 따른 마케팅 커뮤니케이션이라고 간주됩니다. 여기에서 접근할 수 있는 앞서 언급한 정보에 대한 비독립 투자 리서치 및 위험 경고 알림을 읽고, 이해하시기 바랍니다.